Procedural Aspects of Compulsory Licensing Under TRIPS: Report No. II of a Webinar Series on Reinterpreting TRIPS in the Life Sciences

TY - RPRT

T1 - Procedural Aspects of Compulsory Licensing Under TRIPS

T2 - Report No. II of a Webinar Series on Reinterpreting TRIPS in the Life Sciences

AU - Wested, Jakob

AU - Minssen, Timo

PY - 2017/9/28

Y1 - 2017/9/28

N2 - Report from Webinar II, held on 28. June 2017Organization: Jakob Wested, Research Fellow, CIIR, UCPHModerator: Prof. Timo Minssen, CIIR, UCPHPresenter I: Manisha A. Desai, PhD, Assistant General Patent Counsel,Eli Lilly and CompanyPresenter II: Dr. Henning Grosse Ruse-Khan, University of CambridgeIn 2013, Indian authorities granted a compulsory license to NATCO Pharmaceuticals for a patented pharmaceutical product sold by Bayer. This decision raised several complex issues regarding the grant a CL and their consistency with the principles and objectives of TRIPS. Furthermore, in January 2017 an amendment to the TRIPS agreement entered into force, allowing compulsory licensors to export their generic pharmaceuticals to least developed countries (LDC), further recalibrating the intersection between the patent institution and public interest. On this background, the webinar presentations and discussion addressed the framework and context for CL provided by the TRIPS convention. Both the specific requirements enshrined in TRIPS art 31 and the broader objectives and principles enshrined in TRIPS, e.g. transfer and dissemination of technology (art 7), protection of public health (art 8) and technology neutrality (art 27) where included in the discussion.

AB - Report from Webinar II, held on 28. June 2017Organization: Jakob Wested, Research Fellow, CIIR, UCPHModerator: Prof. Timo Minssen, CIIR, UCPHPresenter I: Manisha A. Desai, PhD, Assistant General Patent Counsel,Eli Lilly and CompanyPresenter II: Dr. Henning Grosse Ruse-Khan, University of CambridgeIn 2013, Indian authorities granted a compulsory license to NATCO Pharmaceuticals for a patented pharmaceutical product sold by Bayer. This decision raised several complex issues regarding the grant a CL and their consistency with the principles and objectives of TRIPS. Furthermore, in January 2017 an amendment to the TRIPS agreement entered into force, allowing compulsory licensors to export their generic pharmaceuticals to least developed countries (LDC), further recalibrating the intersection between the patent institution and public interest. On this background, the webinar presentations and discussion addressed the framework and context for CL provided by the TRIPS convention. Both the specific requirements enshrined in TRIPS art 31 and the broader objectives and principles enshrined in TRIPS, e.g. transfer and dissemination of technology (art 7), protection of public health (art 8) and technology neutrality (art 27) where included in the discussion.

KW - Faculty of Law

KW - TRIPS, Life Science, Patents, Compulsory Licensing, Access to Medicine, NATCO

UR - http://jura.ku.dk/ciir/forskning/trips/

M3 - Report

BT - Procedural Aspects of Compulsory Licensing Under TRIPS

CY - Copenhagen

ER -